These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 31441929)
21. Markers of Oxidative Stress, Inflammation and Endothelial Function following High-Dose Intravenous Iron in Patients with Non-Dialysis-Dependent Chronic Kidney Disease-A Pooled Analysis. Kassianides X; White S; Bhandari S Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555659 [TBL] [Abstract][Full Text] [Related]
22. Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease. Ueda N; Takasawa K Nutrients; 2018 Aug; 10(9):. PubMed ID: 30150549 [TBL] [Abstract][Full Text] [Related]
23. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178 [TBL] [Abstract][Full Text] [Related]
24. Plasma neutrophil gelatinase-associated lipocalin is associated with iron status in anemic patients with pre-dialysis chronic kidney disease. Kim IY; Kim JH; Lee DW; Lee SB; Rhee H; Song SH; Seong EY; Kwak IS Clin Exp Nephrol; 2018 Feb; 22(1):28-34. PubMed ID: 28389813 [TBL] [Abstract][Full Text] [Related]
25. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran. Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904 [TBL] [Abstract][Full Text] [Related]
26. Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: a pilot study. Anraku M; Kitamura K; Shintomo R; Takeuchi K; Ikeda H; Nagano J; Ko T; Mera K; Tomita K; Otagiri M Clin Biochem; 2008 Oct; 41(14-15):1168-74. PubMed ID: 18692036 [TBL] [Abstract][Full Text] [Related]
27. Effects of carnitine on oxidative stress response to intravenous iron administration to patients with CKD: impact of haptoglobin phenotype. Armaly Z; Abd El Qader A; Jabbour A; Hassan K; Ramadan R; Bowirrat A; Bisharat B BMC Nephrol; 2015 Aug; 16():135. PubMed ID: 26268514 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis. Susantitaphong P; Alqahtani F; Jaber BL Am J Nephrol; 2014; 39(2):130-41. PubMed ID: 24513913 [TBL] [Abstract][Full Text] [Related]
29. [Iron therapy in chronic kidney disease]. Graczyk M; Kohmann A Wiad Lek; 2016; 69(5):749-752. PubMed ID: 28033601 [TBL] [Abstract][Full Text] [Related]
30. New Options for Iron Supplementation in Maintenance Hemodialysis Patients. Vaziri ND; Kalantar-Zadeh K; Wish JB Am J Kidney Dis; 2016 Mar; 67(3):367-75. PubMed ID: 26616335 [TBL] [Abstract][Full Text] [Related]
31. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Onken JE; Bregman DB; Harrington RA; Morris D; Buerkert J; Hamerski D; Iftikhar H; Mangoo-Karim R; Martin ER; Martinez CO; Newman GE; Qunibi WY; Ross DL; Singh B; Smith MT; Butcher A; Koch TA; Goodnough LT Nephrol Dial Transplant; 2014 Apr; 29(4):833-42. PubMed ID: 23963731 [TBL] [Abstract][Full Text] [Related]
32. The relationship of Prohepcidin levels with anemia and inflammatory markers in non-diabetic uremic patients: a controlled study. Aydin Z; Gursu M; Karadag S; Uzun S; Sumnu A; Doventas Y; Ozturk S; Kazancioglu R Ren Fail; 2014 Sep; 36(8):1253-7. PubMed ID: 25040737 [TBL] [Abstract][Full Text] [Related]
33. C.E.R.A. administered once monthly corrects and maintains stable hemoglobin levels in chronic kidney disease patients not on dialysis: the observational study MICENAS II. MartÃnez-Castelao A; Cases A; Coll E; Bonal J; Galceran JM; Fort J; Moreso F; Torregrosa V; Guirado L; Ruiz P; Nefrologia; 2015; 35(1):80-6. PubMed ID: 25349927 [TBL] [Abstract][Full Text] [Related]
34. Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group. Birgegard G; Samuelsson J; Ahlstrand E; Ejerblad E; Enevold C; Ghanima W; Hasselbalch H; Nielsen CH; Knutsen H; Pedersen OB; Sørensen A; Andreasson B Eur J Haematol; 2019 Mar; 102(3):235-240. PubMed ID: 30472746 [TBL] [Abstract][Full Text] [Related]
35. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress. Swarnalatha G; Ram R; Neela P; Naidu MU; Dakshina Murty KV Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):852-8. PubMed ID: 20814119 [TBL] [Abstract][Full Text] [Related]
36. The association of markers of oxidative-inflammatory status with malnutrition in hemodialysis patients with serum ferritin lower than 500 ng/mL. Almeida SG; Veiga JP; Arruda SF; Neves CF; Siqueira EM J Bras Nefrol; 2013; 35(1):6-12. PubMed ID: 23598746 [TBL] [Abstract][Full Text] [Related]
37. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial. Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Meier Y; Larroque S; Roger SD; BMC Nephrol; 2017 Jan; 18(1):24. PubMed ID: 28095881 [TBL] [Abstract][Full Text] [Related]
38. Iron deficiency anemia in chronic kidney disease: Uncertainties and cautions. Agarwal R Hemodial Int; 2017 Jun; 21 Suppl 1():S78-S82. PubMed ID: 28403561 [TBL] [Abstract][Full Text] [Related]
39. Malnutrition Risk in Hemodialysis Patients in Israel: Results of the Status of Nutrition In Hemodialysis Patients Survey Study. Boaz M; Azoulay O; Schwartz IF; Schwartz D; Assady S; Kristal B; Benshitrit S; Yanai N; Weinstein T Nephron; 2019; 141(3):166-176. PubMed ID: 30654378 [TBL] [Abstract][Full Text] [Related]